About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

UNKNOWNNCT05004961

The Performance of Multi-tracer Multimodality PET in Lymphoma

Investigating the performance of Multi-tracer Multimodality PET in lymphoma

Lead sponsor: Peking University Cancer Hospital & Institute•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Xuejuan Wang, MD

CONTACT

86 010 88196363 xuejuan_wang@hotmail.com

Sponsors

Lead Sponsor

Peking University Cancer Hospital & Institute

In this study investigators evaluated Nodal and Extranodal Lymphoma Lesions uptake by different molecular probe such as FDG, FAPI-04 via multimodality PET (PET/CT and PET/MR). Our Previous studies have shown that uptake of FAPI-04 on PET may be an indicator of lymphoma lesions. The combination of PET with CT/MR allows for depicting metabolic, functional and morphological properties of tumor lesions at the same time, which is therefore an alternative attractive pairing for diagnosis, staging and prognosis of lymphoma.

Age

15 - 80 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•pathologically diagnosed as lymphoma;
•Written informed consent for receiving FAPI-04 PET examinations.
•cancer planned chemotherapy or immunotherapy scheme.
•expected survival ≥ 12 weeks

Exclusion Criteria

•cannot lie supine for half an hour;
•refuse to join the clinical researcher;
•severe liver or kidney dysfunction
•pregnancy or lactation

Related studies

A Multicenter Study Evaluating the Diagnostic Value of 68Ga-MY6349 PET/CT for Prostate Cancer

NCT06696326 · Positron-Emission Tomography(PET), Prostate Cancer, and more

Gene Expression Profiles in Spinal Tuberculosis.

NCT05610098 · Tuberculosis, Spinal, Tuberculosis, Osteoarticular, and more

Trimodal (18)F-choline-PET/mpMRI/TRUS Targeted Prostate Biopsies

NCT02971995 · Prostatic Neoplasm, Positron-Emission Tomography, and more

Diagnostic Significance of Single Center, Open and Prospective Evaluation of <Sup>18<Sup>F-FDG PET/CT Dynamic Imaging and Genomic Sequencing in Detecting Metastatic Lesions of Primary Hepatocellular Carcinoma

NCT03636607 · Positron-Emission Tomography, Carcinoma, Hepatocellular

ImmunoPET Targeting Trophoblast Cell-surface Antigen 2 (Trop-2) in Solid Tumors

NCT06188468 · Tumor, Solid Tumor, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: March 3, 2023Terms

Trial snapshot

StatusUNKNOWN

Phase—

Enrollment200

Start dateSep 2019

Last updatedMar 3, 2023

Condition

Positron-Emission Tomography

Locations shown

Peking University Cancer Hospital

Beijing, Beijing Municipality

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 3, 2023Data synced to Clareo: July 13, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions